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Abstract: The adipocyte-secreted protein adiponectin (APN) has several protective functions in the
peripheral tissues including insulin sensitizing, anti-inflammatory and anti-oxidative effects that may
benefit neurodegenerative diseases such as Alzheimer’s disease (AD). In addition, dysregulation of
cerebral insulin sensitivities and signaling activities have been implicated in AD. Emerging insights
into the mechanistic roles of adiponectin and AD highlight the potential therapeutic effects for AD
through insulin signaling.
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1. Introduction
The central nervous system (CNS) is separated from the peripheral circulations by the blood-brain
barrier (BBB), which stringently controls substance penetration in order to protect the brain from
pathogenic micro-organisms and harmful toxins. The CNS receives and integrates information to
coordinate the whole body’s activities. Intriguingly, peripheral tissues can also produce chemokines
and cytokines to regulate homeostasis and metabolism in the CNS. White adipose tissue is an endocrine
tissue that secretes adipokines, which exert pleiotropic effects in different tissues. Several adipokine
receptors including adiponectin, leptin, and resistin receptors are abundantly expressed in different
brain regions. Dysregulation of adipokine production and/or levels is associated with neurological
and neurodegenerative diseases that can notably be a result of obesity-related metabolic disorders.
In this review, we will discuss the plausible mechanisms of adiponectin (APN) and its protective effects
in Alzheimer’s disease.
1.1. Association between Alzheimer’s Disease and Insulin Signaling
Alzheimer’s disease (AD) is the most common type of age-related neurodegenerative disorder,
accounting for 70% of cases of dementia. Clinical symptoms include impaired spatial learning and
memory decline, particularly the loss of episodic memory. Cognitive decline is a result of progressive
neuronal and synaptic loss. In 1907, Alois Alzheimer described extensive accumulation of extracellular
neuritic plaques and intracellular neuronal fibrillary tangles (NFTs) as two pathological changes
in the brain of a dementia patient [1]. Only three decades ago, the plaque was identified as the
aggregates of Amyloid-β (Aβ) peptide and the NFTs were identified as intracellular aggregates of
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hyperphosphorylated Tau protein [2]. These two pathologies, together with microgliosis, astrocytosis,
neuronal dystrophy and synaptic reduction, represent the hallmarks of AD. In the Aβ hypothesis,
Aβ is one of the major factors of AD pathogenesis as the accumulation of Aβ can induce other AD
pathologies [3–5].
The formation of Aβ is caused by abnormal sequential cleavage of amyloid-precursor protein
(APP) by theβ- and γ-secretases, andβ-site APP-cleaving enzyme 1 (BACE1) is theβ-secretase essential
for Aβ generation. Mutations in APP or presenilin 1 (PS1) and presenilin 2 (PS2), the subunits of
γ-secretase, manifest as early onset familial AD (FAD), in which the levels of Aβ, mainly Aβ40 & Aβ42,
are drastically increased [6]. The mutations may lead to either increased cleavage of APP by
β-secretase or increased levels and aggregation of Aβ [7]. These familial mutations strongly support
the associations between Aβ and AD. Nonetheless, FAD only accounts for 5% of AD cases. Aging is
the major risk factor. Other risk factors included sporadic mutations (e.g., APOEε4), brain trauma,
Down’s syndrome, vascular destruction, or abnormal metabolic functions. These factors can impede
Aβ clearance and trafficking, or enhance Aβ generation, and lead to aberrant cerebral lipid metabolism
and immune responses [8–12]. Substantial studies are ongoing in order to elucidate how these risk
factors are associated with Aβmetabolism, immune responses, or cellular metabolic changes that lead
to AD pathogenesis.
AD has also been described as “Type 3 Diabetes”, since reduced insulin signaling is one of the
major pathophysiological mechanisms in AD patients. Certainly, Type 2 Diabetes Mellitus (T2DM) is
associated with cognitive impairments and considered as a risk factor for AD [13]. There are several
proposed mechanisms that link insulin to AD: (1) high insulin level (hyperinsulinemia) in diabetic
patients leads to the competition of insulin degrading enzyme (IDE) with Aβ and thereby reduces
the clearance of Aβ in the brain; (2) Aβ oligomers can bind to insulin receptors and block the insulin
signaling pathways; (3) Aβ oligomers binding may downregulate insulin receptors via insulin receptor
internalization; and (4) in obese or T2DM subjects who are characterized by increased peripheral levels
of TNFα, TNFα can cross the blood-brain barrier, which results in cerebral insulin resistance due to JNK
activation. Nonetheless, these hypotheses converge in the findings that deregulated insulin signaling
or insulin resistance in the brain activates Glycogen Synthase Kinase 3 (GSK3), which enhances Aβ
production and Tau phosphorylation. Till now, accumulated evidence including human clinical and
animal model studies suggests that AD is a degenerative metabolic disorder associated with impaired
cerebral insulin signaling [14].
Dysregulated Insulin Signaling in Clinical and Animal Studies
In 1994, Razay G. found that AD patients had peripheral hyperinsulinemia, insulin resistance and
were overweight, describing the possible association between insulin signaling and AD [15]. Since then,
different reports have highlighted that AD patients may have reduced insulin signaling activities in the
brain. Though AD patients were found with peripheral hyperinsulinemia, AD patients have reduced
levels of insulin in the cerebrospinal fluid (CSF), indicating that insulin signaling activities may be
below the normal threshold in the brain [16]. This was proven by elevated levels of phosphorylated
insulin receptor substrate 1 (pIRS-1) with phosphorylation at serine 616 and serine 636 residues and
reduced pAkt level in the post mortem brain [14,17]. Lower levels of insulin receptor (IR) and insulin
receptor substrate 1/2 (IRS1/2) were also found in the AD brain [18,19]. These lines of evidence
support the increase of activated GSK3β levels found in AD patients [20]. AD patients have reduced
CSF insulin levels that inversely correlated with Aβ42 levels. Late middle-aged subjects who had
peripheral insulin resistance displayed reduction in cerebral glucose uptake, increased Aβ42 and pTau
levels in CSF [21,22]. These indicated that insulin resistance and downregulated insulin signaling
activities are associated with AD pathologies in patients.
The correlation between downregulated insulin signaling and AD pathology was further
established in animal studies. Insulin deficiency induced by streptozotocin (STZ) in transgenic AD
mice accelerated β-amyloidosis through post-translational upregulation of BACE [22]. Peripheral
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administration of STZ in mice reduced cerebral pAkt and pGSK3βSer9 levels, and exacerbated Tau
pathology, synaptic proteins reduction and memory deficits. However, STZ-treated Tau knockout mice
had reduced phenotypes, indicating that insulin deficiency and reduced insulin signaling is a cause of
Tau-mediated cognitive impairments [23].
1.2. Enhancing Insulin Signaling as a Treatment for AD
Hence, restoring cerebral insulin levels and its signaling activities has become a therapeutic target
for AD treatment. It is hypothesized that increasing CNS insulin levels can improve memory functions
and reduce AD phenotypes. Intranasal administration of insulin has been proposed since insulin
can be degraded by digestive enzymes and therefore cannot be orally administered. This approach
has been studied and has shown promising results in both animal and AD patient models [24–29].
Unfortunately, no significant change in the CSF Aβ and Tau levels were detected in AD patients after
intranasal insulin treatment. Notably, there is a theoretical concern that chronic high insulin levels
with prolonged intranasal insulin treatment may induce cerebral insulin resistance. This is highly
possible since excessive exposure to insulin in vivo and in vitro can induce insulin resistance models
with decreased pAkt and pGSK3βSer9 levels.
2. Adiponectin
Adiponectin is an adipocyte-derived hormone that was discovered in 1995 from 3T3-L1
adipocytes [30]. It was thought to be exclusively secreted by adipose tissue until it was found to
be also expressed in hepatocytes, myocytes, osteoblasts and epithelial cells. This adipokine is secreted
to the circulation and functions as an endocrine hormone to regulate glucose and lipid metabolism [31].
APN has a molecular weight of about 30 kDa containing 244 amino acids (247 amino acids for
mouse ortholog). It consists of four domains, including a signaling peptide region, a species-specific
variable with cysteine residue for oligomerization, a collagenous domain comprising 22 Gly-X-Y
repeats that enhances the triple helix formation in its protein structure, and a globular domain which
facilitates the binding with its receptors. The full length APN protein shares structural similarities with
tumor necrosis factor-α (TNFα), complement factor-1 (C1q), collagens VIII and X. The trimeric APN
is the basic form in circulation that is stabilized by hydrophobic interactions between the globular
domains. Trimeric adiponectin can further undergo post-translational modification to form hexamers
and high molecular weight (HMW) multimers by non-covalent disulphide bonds between the cysteine
Cys36 residues (Cys39 in mouse) [32–34]. A globular fraction, globular adiponectin (gAPN) is also
found in circulation post-translationally cleaved from the full length APN monomer [35]. All of these
fractions account for about 0.01% of the total protein in human serum (0.05% in rodent). However,
the trimeric and globular levels are comparatively low in plasma whereas the hexameric and HMW
APN are the major forms in circulation. The physiological levels of adiponectin are generally higher
in females and decrease with age in both sexes [36]. Moreover, the levels of circulating APN are also
affected by various conditions including hormonal and nutritional factors, the levels of circulating
cytokines, disease states, chronic inflammation and exercise [37,38]. It is well known that there
is an inverse association between circulating APN levels and obesity/insulin resistance as well as
T2DM [39,40].
2.1. Adiponectin Receptors and Adiponectin Signaling
Adiponectin can act on various tissues to provide insulin sensitizing, anti-inflammatory,
anti-oxidative and anti-atherogenic effects. Two main receptors modulate APN signaling transduction;
adiponectin receptor 1 (AdipoR1) and adiponectin receptor 2 (AdipoR2). These two receptors are
differentially expressed in the liver, skeletal muscle, cardiac muscle, osteoblasts, adipose tissues,
pancreas, leukocytes, endothelial cells, and the brain. Adaptor protein, phosphotyrosine interacting
with PH domain and leucine zipper 1 (APPL1) binds to both AdipoRs and serves as a link between
receptors and the downstream signaling molecules. The signaling molecules activated by adiponectin
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include AMPK, p38MAPK, ERK1/2-MAPK and PPARα. Among these, AMPK acts as the main
downstream effector of adiponectin. Numerous evidence has shown that Adiponectin-AdipoR1-AMPK
activation provides various beneficial metabolic and protective effects to different tissues. AMPK
mediates APN signaling to enhance insulin sensitivity through mTOR-p70S6K inhibition and serine
phosphorylation of IRS-1 [41] in skeletal muscle. APN also activates AMPK, which phosphorylates
acetyl-CoA carboxylase (ACC), enhances fatty acid oxidation, glucose uptake and utilization in liver,
muscle [42] and adipocytes [43]. Signaling via AdipoR1 increases IRS-1 expression and activates APPL1
which promotes IRS-1/2 binding to insulin receptors [44,45]. Besides improving insulin sensitivity
and glucose metabolism, APN exerts anti-inflammatory activities by counteracting the actions of
inflammatory cytokines. APN can suppress TNFα production through the inhibition of p38MAPK and
TNFα-mediated inflammatory signaling from macrophages [46–48]. It also blocks the action of TNFα
and IL1β in lung epithelial tissues [49]. Last but not least, APN provides protection from oxidative
stress-mediated cytotoxicity by reducing the production of reactive oxidative stress through AMPK
signaling [50–52].
2.2. Adiponectin in the Brain
In contrast to substantial information about the roles of APN in peripheral tissues, the effect
of adiponectin in the CNS is largely unknown. APN is not expressed in the brain. However,
intracerebroventricular (ICV) injection of APN stimulated the paraventricular nucleus, a region
involved in energy hemostasis. ICV injection of APN decreased weight gain in mice by increasing
energy expenditure [53]. It was first suggested that APN was unable to cross the blood-brain barrier
and could not be detected in the CSF [54,55], until several reports showed that APN was detectable in
the CSF of patients with unspecified neurological disorders and in healthy subjects after IV injection
of APN [56–59]. This may be due to the sensitivity of the analytical methods, as the CSF APN level
is 1000-fold lower than the plasma level [56]. The distribution of APN oligomers in the CSF differs
from that of the serum. Above 80% of the CSF APN is trimeric and the remaining 20% is constituted
by other low molecular weight (LMW) adiponectin isoforms (e.g., hexamers) [57]. Similar experiments
have been performed in mice and have shown that APN levels in the mouse CSF is 100-fold lower
than plasma levels [53,60]. AdipoR1 and AdipoR2 are also highly expressed in different brain regions,
including the hypothalamus, cortex, hippocampus, pituitary glands, and area postrema [61].
The physiological functions of APN in the CNS were first identified in association with food
intake and body weight control [53]. It acts on the hypothalamus and activates AdipoR1-AMPK
signaling to regulate food intakes, energy expenditure, and lipid and glucose metabolism during
fasting [62,63]. Central administration of APN improves hypothalamic insulin signaling activities in
diabetic rats and improves glucose homeostasis [64]. APN regulates neurogenesis and proliferation
of hippocampal neural stem cells [60,65]. In addition, APN deficiency reduces dendritic growth and
spine density in the hippocampal dentate gyrus in which the neural progenitor cells proliferation
and differentiation is suppressed [66]. Besides neuroanatomical values, APN is also important in
psychological functions. APN knockout (APN-KO) mice exhibit depressive-like behavior [67]. Physical
activities and environmental enrichment can increase cerebral APN levels, which exert anti-depressive
effects, increase hippocampal neurogenesis, and reduce neuroinflammation in mice [60,68,69]. Loss of
APN in mice also exacerbates the severity of encephalomyelitis by activating lymphocytes in the mouse
model of multiple sclerosis [70]. APN has anti-inflammatory and anti-atherosclerotic effects in the
periphery. It is suggested that it also exerts a protective effect against ischemic brain injury. Clinical
reports revealed an association between decreased APN levels and ischemic stroke. Adiponectin gene
polymorphisms are associated with the risk of ischemic stroke [71,72]. Expression of adiponectin
in vascular endothelial cells was increased in mice after cerebral ischemia/reperfusion injury [73].
APN treatment in mice protected the integrity of the blood-brain barrier against cerebral ischemic
injury by suppressing the expression of inflammatory cytokines, and it also improved neurobehavioral
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performance and focal cerebral neurogenesis [74]. In summary, APN not only controls metabolism
through the hypothalamic-pituitary axis, but also exerts enormous protective effects to the CNS.
3. Pathophysiological Roles of Adiponectin in Alzheimer’s Disease
Adiponectin has protective effects to the CNS. Studies have been conducted to investigate the
roles of adiponectin in neurodegenerative disease. In 2011, Une et al. found increased CSF APN in
patient with mild cognitive impairment (MCI) but not in AD patients, when compared with control
subjects [75]. A year after the report by Une et al. was published, a prospective clinical study
concluded the increased plasma adiponectin level is an independent risk factor for dementia and AD in
women [76]. Texixeira A.L. and his colleagues found reduced serum adiponectin levels in MCI and AD
patients with similar subject size [77]. More recently, Wennberg et al. found that the serum adiponectin
is positively correlated to the levels of amyloid but inversely correlated to the hippocampal volume in
women with MCI [78]. Waragi et al. revealed a reduction of CSF APN levels in AD patients correlating
to an increase of CSF Aβ42, CSF p-Tau and the presence of hippocampal atrophy. This research
group also suggested that an increase of circulating adiponectin levels could be a compensatory effect
against neurodegeneration [79]. In contrast to previous findings, another report showed no significant
difference of adiponectin levels between a non-demented group and patients with dementia [80].
Furthermore, Yu et al. found correlations between adiponectin gene polymorphism and late onset
AD [81]. Two studies reported on low adiponectin levels in T2DM patients who had reduced gray
matter volume, hippocampal volume and glucose metabolism, to be consistent with Alzheimer’s
disease pathophysiologies [79,82]. Another group reported that T2DM patients with MCI had lowered
serum adiponectin levels [83]. Besides human patients, Kurata et al. showed the reduction of serum
APN levels in APP transgenic mice [84]. Adiponectin transport to the brain decreased with age while
peripheral APN levels showed no difference between young and aged rats [85]. This indicated that
the cerebral APN may be important for memory and learning. However, these clinical studies cannot
provide insight regarding the causality of adiponectin to AD. These studies only revealed associations
or correlations, and showed variation among different study groups. No cause-and-effect study
had been conducted until we recently reported that chronic adiponectin deficiency elicited AD-like
phenotypes, pathologies and cognitive impairments with cerebral insulin resistance in aged mice [86].
In 2012, we showed that APN was neuroprotective against oxidative stress-induced cytotoxicity
under Aβ toxicity in vitro [87]. We hypothesized that hypoadiponectinemia may lead to Aβ
accumulation, which is neurotoxic and may result in neurodegeneration. Recently, we found that aged
mice with chronic adiponectin deficiency had memory decline, spatial learning impairment, increased
anxiety, and impaired contextual fear conditioning. Deregulated cerebral insulin signaling activities
and reduced hippocampal insulin sensitivity developed during the aging of APN-KO mice. Aberrant
activation of GSK3β was revealed by reduced pGSK3βS9 and increased pGSK3βY279 levels in aged
APN-KO mice. These findings provide an explanation for the dramatic increase of phosphorylated
Tau, increased Aβ42 production and Thioflavin S positively stained Aβ deposition. Intriguingly,
we detected Aβ*56 in the brain of aged APN-KO mice whereas it was absent in the brain of the
wild-type mice. Moreover, we found increased microgliosis, astrogliosis with increased cerebral TNFα
and IL1β levels that are the common hallmarks of AD. The reduced synaptic proteins levels and
increased neuronal apoptosis also indicated that chronic adiponectin deficiency was associated with
neurodegeneration in aging (Figure 1). Adiponectin-treated SH-SY5Y neuroblastoma cells carrying
APPswedish mutation had reduced extracellular Aβ42 peptide. SH-SY5Y neuroblastoma cells treated
with high concentration of insulin displayed insulin resistance with reduced pAkt level. The insulin
sensitivity of the insulin resistant SH-SY5Y was restored after treatment with exogenous trimeric
adiponectin protein through the activation of AMPK. Our findings provide strong evidence that
reduced adiponectin is associated with deregulated cerebral insulin signaling and AD pathogenesis in
aged or T2DM subjects who have decreased CNS adiponectin levels [86].
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adiponectin deficiency leads to an increase of IRS-1 phosphorylation at serine residues (e.g., Serine 
616). This causes reduced pIRS-1Tyr and results in GSK3 activation. Activated GSK3 enhances Tau 
phosphorylation and Aβ production in neurons. Arrows denote promotion, T-bars denote 
inhibition. 
In summary, it is hypothesized that the decrease of APN levels or reduction in adiponectin 
signaling activities can be a cause of AD pathogenesis and cognitive impairments. The association is 
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brain. 
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acetylcholinesterase inhibitors that are marketed drugs for the symptomatic treatment of AD. 
Intriguingly, the serum adiponectin levels progressively increased in AD patients who were 
administered with Donepezil [91]. Adiponectin has been considered as a therapeutic target to treat 
metabolic syndromes because of its potent protective effects to both the CNS and peripheral tissues. 
Figure 1. Pathophysiological roles of adiponectin in Alzheimer’s disease (AD). Schematic outline of
neuronal adiponectin signaling in the normal brain (A); and adiponectin-deficient brain (B). Under
physiological conditions, adiponectin binds to its receptor and triggers phosphorylation of AMPK
which in ibits IRS-1 phosphorylat on at serine residues. This increases insulin-med ated IRS-1
phosphorylatio at tyrosine residues and promotes downstream Akt-mediated GSK3 i hibition.
Inhibition of GSK3 slows down phosphorylation of Tau and APP metabolism. In AD, chronic
adiponectin deficiency leads to an increase of IRS-1 phosphorylation at serine residues (e.g., Serine 616).
This causes reduced pIRS-1Tyr and results in GSK3 activation. Activated GSK3 enhances Tau
phosphorylation and Aβ production in neurons. Arrows denote promotion, T-bars denote inhibition.
It is suggested that rodents do not develop amyloid pathologies, probably because of the longevity
and low aggregating propensity of rodent Aβ. Mice with a specific gene knocked out or carrying
mutated human APP or PS transgene have increased Aβ deposition and generation. We found that
the aged APN-KO mice had increased GSK3β activity with increased Aβ production. A recent report
indicates that the inhibition of GSK3β activity can decrease BACE1 expression, which results in reduced
Aβ production [88]. We also found increased formation of a specific Aβ oligomer (Aβ*56) in aged
APN-KO mice with no dimeric or trimeric Aβ bein detected. Aβ*56 is a specific Aβ oligomer found
in patients with MCI and transgenic AD mice at a young age [89]. Aβ*56 leads to dose-dependent
cognitive decline in mice, whereas trimeric Aβ does not [90]. Though the detailed mechanism of how
adiponectin regulates the formation of Aβ*56 remains unknown, adiponectin deficiency promotes
rodent Aβ production through GSK3β-mediated activities.
In summary, it is hypothesized that the decrease of APN levels or reduction in adiponectin
signaling activities can be a cause of AD pathogenesis and cognitive impairments. The association is
highly linked to the deregulated insulin signaling activities and reduced insulin sensitivity in the brain.
4. Therapeutic Potential of Adiponectin
Effective treatment or medication for AD is currently limited. Donepezil is one of the
four acetylcholinesterase inhibitors that are marketed drugs for the symptomatic treatment of
AD. Intriguingly, the serum adiponectin levels progressively increased in AD patients who were
administered with Donepezil [91]. Adiponectin has been considered as a therapeutic target to treat
metabolic syndromes because of its potent protective effects to both the CNS and peripheral tissues.
However, adiponectin cannot be orally administered due to its protein nature. Intravenous injection of
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recombinant adiponectin protein can by-pass the digestive system, but prolonged injection treatments
are costly. The inventions of pharmacological agents or changes of lifestyle to elevate endogenous
adiponectin expression or activate adiponectin signaling may pave the road for future AD treatment.
Physical exercise has long been considered to exert beneficial effects on brain functions, improve
psychiatric symptoms and delay progression of neurodegenerative diseases. Increase of peripheral
adiponectin levels and transport of adiponectin across the BBB were reported in rodents and human
with increased physical exercise. Peroxisome proliferator-activated receptor γ (PPARγ) agonist
increases adiponectin expression and exerts insulin-sensitizing effects. PPARγ agonist such as
pioglitazone is an approved medication to T2DM patients. Repositioning of pioglitazone to treat
AD is under investigation. AD mice fed with pioglitazone have shown cognitive improvements and
suppressed microglial reactivation. However, it is known that pioglitazone crosses the BBB weakly
and whether it works through adiponectin to exert neuroprotection remains uncertain (Figure 2).
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Figure 2. Strategies to increase adiponectin signaling in AD neurons. Peripherally, adiponectin
expression from the liv r, a i ocytes and muscle can be incr ased by admini tering PPARγ agonist
(e.g., pioglitazone) and physical exercise induction. Physical exercise can also increase the transport of
low molecular weight nd trimeric adiponectin across the blood-brain barrier (BBB). Administration
of adipoR agonists and LMW adiponectin acts on AdipoR1 in neurons and microglia to exert
neuroprotection. Green arrow denotes increase, arrows and dash arrows denote promotion, T-bars
denote inhibition.
More ece tly, several ad ponectin receptor agonists have b en iscovered. In 2013, several
adiponectin receptor 1 ago ists were discovered including matairesinol, arctiin, arctigenin and
gramine from the screening of 10,000 natural compounds [92]. Concomitantly, in the same year,
arctigenin was found to improve memory functions in the AD mice model that suppressed
Aβ production by inhibiting BACE1 activity and enhanced autophagic clea nce of Aβ by
Akt-mTOR inhibition and AMPK activation. Last but not the least, osmotin, a plant homolog
of mammalian adiponectin, was identified as a novel adipoR1 agonist which is neuroprotective
against ethanol-induced apoptosis and glutamate-induced synaptic dysfunction in rat brain. It also
suppresses Aβ-induced memory impairments, Tau phosphorylation and neurodegeneration in mouse
hippocampus. Furthermore, it modulates microglia activation against LPS-induced neuroinflammation
through AdipoR1-TLR4/NF-κB signaling cascade [93]. Notably, osmotin was found to improve
synaptic functions and cognitive functions, and diminish Aβ production and aggregation through
AdipoR1-AMPK-SIRT1 pathway.
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5. Conclusions
It is indicated that hypoadiponectinemia in the brain may be implicated in neurodegeneration
during aging. The reduced adiponectin levels in T2DM patients may be a factor which increases
the risk of AD. T2DM patients or subjects with chronic adiponectin deficiency may develop cerebral
insulin resistance. Decreased cerebral insulin signaling activities promotes Aβ production and Tau
phosphorylation, causing neuroinflammation and neurodegeneration. Regarding its neuroprotective
roles including insulin sensitizing, anti-inflammatory and anti-oxidative effects, adiponectin may pave
the road to prevent and treat Alzheimer’s disease.
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Abbreviations
AD Alzheimer’s disease
Aβ Amyloid-β
AdipoR Adiponectin receptor
AMPK 5′ adenosine monophosphate-activated protein kinase
APN Adiponectin
APP Amyloid precursor protein
APPL1 Adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1
BACE1 β-site APP cleaving enzyme 1
BBB Blood-brain barrier
CNS Central nervous system
ERK1/2 Extracellular signal-regulated kinase1/2
FAD Familial Alzheimer’s disease
GSK Glycogen synthase kinase
HMW High molecular weight
ICV Intracerebroventricular
IV Intravenous
IDE Insulin degrading enzyme
IL1β Interleukin 1β
IR Insulin receptor
IRS-1 Insulin receptor substrate 1
JNK c-Jun N-terminal kinase
LMW Low molecular weight
LPS Lipopolysaccharide
MAPK Mitogen-activated protein kinases
MCI Mild cognitive impairment
NFT Neurofibrillary tangles
mTOR mammalian target of rapamycin
NF-κB Nuclear factor κ B
PPARα Peroxisome proliferator-activated receptor α
PPARγ Peroxisome proliferator-activated receptor γ
PS Presenilin
SIRT-1 NAD-dependent deacetylase sirtuin-1
T2DM Type 2 diabetes mellitus
TLR4 Toll-like receptor 4
TNFα Tumor necrosis factor α
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